Vertex Pharmaceuticals: Looking For Signs Of Success In Q1 Earnings

Vertex Pharmaceuticals remains the leader in cystic fibrosis but is now executing a tangible diversification into pain, renal ...
Seeking Alpha

Vertex outlines $823.5M–$831.5M 2026 revenue target as new CEO prioritizes AI-first transformation

Schwab provided 2026 guidance: "For the full year of 2026, we expect revenues of $823.5 million to $831.5 million, cloud revenue growth of 25% and adjusted EBITDA of $188 million to $192 million, ...
Reuters

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Feb 12 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab forecast 2026 revenue largely in line with analysts estimates on Thursday, as the drugmaker bets on growth for its cystic fibrosis ...
Hosted on MSN

Vertex reiterates $11.85B–$12B 2025 revenue guidance while boosting JOURNAVX commercial investment

Wagner reiterated Vertex's 2025 total revenue guidance of $11.85 billion to $12 billion, representing approximately 8% growth at midpoint. This outlook reflects ongoing ALYFTREK and CASGEVY launches, ...
The Motley Fool

Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash

Vertex Pharmaceuticals is the leader in cystic fibrosis treatment. The company has also expanded into other areas in recent years, winning approval for two new drugs. Vertex is the global leader in ...